Olympus

• Enhance libido
• Increases sexual receptivity
• Induces rapid onset of arousal
• Improves erection quality and sensitivity
• Flexible dosing options for varied lifestyles

• The medication is designed to work when there is an initial sexual stimulus
• Dose adjustments should aim for the lowest appropriate dose to limit side effects and improve adherence and increase to effect if needed

• Caution in patients with current history of either active ingredients
• Contraindicated in individuals with a known hypersensitivity or allergy to methionine, inositol, choline, cyanocobalamin, or any component of the formulation
• Discontinue use and seek medical evaluation if unexpected or severe reactions occur
• Side effects such as nausea, flushing, headache, tachycardia, dizziness, nasal congestion, have been reported

• Increases sexual receptivity
• Causes erection during sexual arousal
• Affects sexual function via the hypothalamus, causing a more natural sexual response
• Induces rapid onset of arousal
• Increases erection in 80% of males who did not respond to traditional therapy
• In women with low sexual desire, bremelanotide will promote increased vaginal blood flow and amplified sexual arousal

Q: How long does it take to see results? 

A: Typical onset is 30 minutes after taking. If no effect is seen, you may need to increase your dose up to a max of 1 full tablet per 24 hours.

Q: Can I use this with other medications? 

A: It can be used with other medications.

Q: What if I miss a dose? 

A: This medication is designed to be used as needed 30 minutes prior to sexual activity. There is no need to take it as a daily dosing unless needed.

1. Melis MR, Argiolas A. Oxytocin, Erectile Function and Sexual Behavior: Last Discoveries and Possible Advances. Int J Mol Sci. 2021 Sep 26;22(19):10376. doi: 10.3390/ijms221910376. PMID: 34638719; PMCID: PMC8509000.
2. Oti T, Sakamoto H. Neuropeptidergic control circuits in the spinal cord for male sexual behaviour: Oxytocin-gastrin-releasing peptide systems. J Neuroendocrinol. 2023 Sep;35(9):e13324. doi: 10.1111/jne.13324. Epub 2023 Jul 29. PMID: 37515539.
3. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild- to- moderate erectile dysfunction. Int J Impot Res. 2004 Feb;16(1):51-9. doi: 10.1038/sj.ijir.3901139. PMID: 14963471.
4. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. PMID: 31599840; PMCID: PMC6819021.
5. Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020 Jul;54(7):684-690. doi: 10.1177/1060028019899152. Epub 2020 Jan 1. PMID: 31893927.
6. Oxytocin. Prescribing information. DailyMed. National Library of Medicine. Revised January 12, 2025. Accessed February 26, 2026
7. Bremelanotide. Prescribing information. DailyMed. National Library of Medicine. Revised November 13, 2025. Accessed February 26, 2026